Related references
Note: Only part of the references are listed.Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2020)
[F-18]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
Rachel M. Glicksman et al.
BMJ OPEN (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips et al.
JAMA ONCOLOGY (2020)
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Claire L. Vale et al.
LANCET (2020)
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler et al.
JAMA ONCOLOGY (2019)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature
Wee Loon Ong et al.
BJU INTERNATIONAL (2019)
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S. Hofman et al.
BJU INTERNATIONAL (2019)
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol
Michael S. Hofman et al.
BJU INTERNATIONAL (2018)
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
Shankar Siva et al.
EUROPEAN UROLOGY (2018)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen et al.
EUROPEAN UROLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges
So Won Oh et al.
KOREAN JOURNAL OF RADIOLOGY (2018)
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography
Andrew Kneebone et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo Ruers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo Ruers et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists
Stephen L. Lewis et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
PET/CT with C-11-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
Stefano Fanti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2016)
Prospective Comparison of F-18-Fluoromethylcholine Versus Ga-68-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
Joshua J. Morigi et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Markus Dietlein et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Initial Evaluation of [F-18]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
Zsolt Szabo et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer
Michael Souvatzoglou et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis
Martin H. Umbehr et al.
EUROPEAN UROLOGY (2013)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Share Paper
